Mainz Biomed B.V. Statistics
Share Statistics
Mainz Biomed B.V. has 2.00M shares outstanding. The number of shares has increased by 7.51% in one year.
Shares Outstanding | 2.00M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.86M |
Failed to Deliver (FTD) Shares | 1.10M |
FTD / Avg. Volume | 32.88% |
Short Selling Information
The latest short interest is 1.52M, so 2.61% of the outstanding shares have been sold short.
Short Interest | 1.52M |
Short % of Shares Out | 2.61% |
Short % of Float | 3.27% |
Short Ratio (days to cover) | 0.61 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is -0.37.
PE Ratio | -0.72 |
Forward PE | -0.37 |
PS Ratio | 21.04 |
Forward PS | 4.6 |
PB Ratio | 5.8 |
P/FCF Ratio | -0.79 |
PEG Ratio | n/a |
Enterprise Valuation
Mainz Biomed B.V. has an Enterprise Value (EV) of 19.19M.
EV / Earnings | -0.73 |
EV / Sales | 21.43 |
EV / EBITDA | -0.77 |
EV / EBIT | -0.72 |
EV / FCF | -0.81 |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 1.84.
Current Ratio | 0.97 |
Quick Ratio | 0.91 |
Debt / Equity | 1.84 |
Total Debt / Capitalization | 64.74 |
Cash Flow / Debt | -3.68 |
Interest Coverage | -32.91 |
Financial Efficiency
Return on equity (ROE) is -8.09% and return on capital (ROIC) is -249.72%.
Return on Equity (ROE) | -8.09% |
Return on Assets (ROA) | -1.71% |
Return on Capital (ROIC) | -249.72% |
Revenue Per Employee | 13.78K |
Profits Per Employee | -404.55K |
Employee Count | 65 |
Asset Turnover | 0.06 |
Inventory Turnover | 0.63 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 407.69% in the last 52 weeks. The beta is 0.08, so Mainz Biomed B.V.'s price volatility has been higher than the market average.
Beta | 0.08 |
52-Week Price Change | 407.69% |
50-Day Moving Average | 4.82 |
200-Day Moving Average | 1.66 |
Relative Strength Index (RSI) | 42.77 |
Average Volume (20 Days) | 3.33M |
Income Statement
In the last 12 months, Mainz Biomed B.V. had revenue of $895.48K and earned -$26.30M in profits. Earnings per share was $-1.62.
Revenue | 895.48K |
Gross Profit | 509.66K |
Operating Income | -26.64M |
Net Income | -26.30M |
EBITDA | -25.01M |
EBIT | -26.64M |
Earnings Per Share (EPS) | -1.62 |
Balance Sheet
The company has $7.07M in cash and $7.42M in debt, giving a net cash position of -$349.86K.
Cash & Cash Equivalents | 7.07M |
Total Debt | 7.42M |
Net Cash | -349.86K |
Retained Earnings | -69.33M |
Total Assets | 15.41M |
Working Capital | -257.15K |
Cash Flow
In the last 12 months, operating cash flow was -$21.94M and capital expenditures -$1.90M, giving a free cash flow of -$23.84M.
Operating Cash Flow | -21.94M |
Capital Expenditures | -1.90M |
Free Cash Flow | -23.84M |
FCF Per Share | -1.47 |
Margins
Gross margin is 56.91%, with operating and profit margins of -2.98K% and -2.94K%.
Gross Margin | 56.91% |
Operating Margin | -2.98K% |
Pretax Margin | -2.94K% |
Profit Margin | -2.94K% |
EBITDA Margin | -2.79K% |
EBIT Margin | -2.98K% |
FCF Margin | -2.66K% |
Dividends & Yields
MYNZ does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -30.68% |
FCF Yield | -225.45% |
Analyst Forecast
The average price target for MYNZ is $3, which is -43.2% lower than the current price. The consensus rating is "Hold".
Price Target | $3 |
Price Target Difference | -43.2% |
Analyst Consensus | Hold |
Analyst Count | 2 |
Stock Splits
The last stock split was on Dec 3, 2024. It was a backward split with a ratio of 1:40.
Last Split Date | Dec 3, 2024 |
Split Type | backward |
Split Ratio | 1:40 |
Scores
Altman Z-Score | -11.14 |
Piotroski F-Score | 3 |